Department of Clinical Microbiology, Health Sciences Centre/Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9.
Diagn Microbiol Infect Dis. 2011 Mar;69(3):348-55. doi: 10.1016/j.diagmicrobio.2010.10.032.
The in vitro activity of ceftobiprole was evaluated against 15 011 clinical isolates obtained from patients in Canadian hospitals between 2007 and 2009. All Staphylococcus aureus were susceptible to ceftobiprole (MIC(90)'s for methicillin-susceptible Staphylococcus aureus and methicillin-resistant Staphylococcus aureus of ≤ 1 μg/mL and 2 μg/mL, respectively). Ceftobiprole was active against penicillin-susceptible Streptococcus pneumoniae (MIC(90), ≤ 0.06 μg/mL), penicillin-resistant Streptococcus pneumoniae (MIC(90), 0.5 μg/mL), Streptococcus pyogenes (MIC(90), ≤ 0.06 μg/mL), Staphylococcus epidermidis (MIC(90), ≤ 1 μg/mL), and Enterococcus faecalis (MIC(90), ≤ 1 μg/mL). Over 90% of Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Citrobacter freundii, Proteus mirabilis, and Serratia marcescens isolates were inhibited by a ceftobiprole concentration of ≤ 1 μg/mL. Ceftobiprole was not active against extended-spectrum β-lactamase-producing Escherichia coli and K. pneumoniae. The in vitro activity of ceftobiprole versus Pseudomonas aeruginosa was similar to that of cefepime (MIC(90), 16 μg/mL). The broad spectrum of activity by ceftobiprole would support further study of this agent in the treatment of hospital-acquired infections.
2007 年至 2009 年间，从加拿大医院的患者中获取了 15011 株临床分离株，评估了头孢洛林的体外活性。所有金黄色葡萄球菌均对头孢洛林敏感（甲氧西林敏感金黄色葡萄球菌和耐甲氧西林金黄色葡萄球菌的 MIC90 分别为≤1μg/ml 和 2μg/ml）。头孢洛林对青霉素敏感肺炎链球菌（MIC90，≤0.06μg/ml）、青霉素耐药肺炎链球菌（MIC90，0.5μg/ml）、化脓性链球菌（MIC90，≤0.06μg/ml）、表皮葡萄球菌（MIC90，≤1μg/ml）和粪肠球菌（MIC90，≤1μg/ml）具有活性。超过 90%的大肠埃希菌、肺炎克雷伯菌、阴沟肠杆菌、弗劳地柠檬酸杆菌、奇异变形杆菌和粘质沙雷氏菌分离株被头孢洛林浓度≤1μg/ml 抑制。头孢洛林对产超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌没有活性。头孢洛林对铜绿假单胞菌的体外活性与头孢吡肟相似（MIC90，16μg/ml）。头孢洛林的广泛活性谱将支持进一步研究该药物在治疗医院获得性感染中的应用。
Zotero 插件